NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Nanoparticle albumin bound paclitaxel for the first line treatment of metastatic malignant melanoma [ID570]

Provisional matrix of consultees and commentators (pre-referral)

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Celgene (nanoparticle albumin bound paclitaxel)	 Allied Health Professionals Federation Board of Community Health Councils in Wales
Patient/carer groups	British National Formulary
Afiya Trust	Care Quality Commission
Black Health AgencyCancer Black Care	Commissioning Support Appraisals Service
Cancer Equality	Department of Health, Social Services
Cancer 52	and Public Safety for Northern Ireland
Equalities National Council	Healthcare Improvement Scotland
Factor 50	Medicines and Healthcare products
Helen Rollason Heal Cancer Charity	Regulatory Agency
Independent Age	National Association of Primary Care
Macmillan Cancer Support	National Pharmacy Association
 Maggie's Centres Marie Curie Cancer Care 	 NHS Alliance NHS Commercial Medicines Unit
 Marie Curie Cancer Care Muslim Council of Britain 	 NHS Confideration
Muslim Health Network	 Public Health Wales NHS Trust
 Rarer Cancers Foundation 	 Scottish Medicines Consortium
Skcin - Karen Clifford Skin Cancer	
Charity	Possible comparator manufacturer(s)
South Asian Health Foundation	Hospira UK (dacarbazine)
Specialised Healthcare Alliance	Lipomed (dacarbazine)
Tenovus	Medac UK (dacarbazine)
Professional groups	
Association of Cancer Physicians	Relevant research groups
British Association for Services to the	British Society for Dermatological
Elderly	Surgery
British Association of Surgical	Cochrane Skin Group
Oncology (BASO)	Health Research Authority
British Association of Dermatologists	Institute of Cancer Research MBC Clipical Trials Upit
British Association of Skin Cancer Specialist Nursee	MRC Clinical Trials Unit Mytanywy Townsond Melanomo
Specialist Nurses	Myfanwy Townsend Melanoma

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of nanoparticle albumin bound paclitaxel for the first line treatment of metastatic malignant melanoma [ID570] Issue date: April 2013 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
 British Dermatological Nursing Group British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Skin Foundation Cancer Network Pharmacists Forum Cancer Research UK Melanoma Focus Primary Care Dermatology Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal Society of Medicine Society and College of Radiologistps United Kingdom Clinical Pharmacy Association United Kingdom Oncology Nursing Society 	 Research Fund National Cancer Research Institute National Cancer Research Network National Institute for Health Research Research Institute of the Care of Older People Skin Cancer Research Fund Skin Research Centre Skin Treatment & Research Trust Evidence Review Group Evidence Review Group tbc National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Collaborating Centre for Cancer Associated Public Health Groups tbc
Others Department of Health Welsh Government Clinical commissioning group tbc Clinical commissioning group tbc	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence Provisional matrix for the proposed technology appraisal of nanoparticle albumin bound paclitaxel for the first line treatment of metastatic malignant melanoma [ID570] Issue date: April 2013 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Care Excellence

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Provisional matrix for the proposed technology appraisal of nanoparticle albumin bound paclitaxel for the first line treatment of metastatic malignant melanoma [ID570] Issue date: April 2013 Page 3 of 3